{
 "ticker": "HELX",
 "name": "Franklin Genomic Advancements ETF",
 "issuer": "Franklin",
 "desk": "themes",
 "url": "https://etfiq.com/funds/helx",
 "html": "https://etfiq.com/funds/helx",
 "markdown": "https://etfiq.com/funds/helx.md",
 "as_of": "2026-09-11",
 "verdict": "HELX holds 61 stocks, and 85% of its weight is outside the S&P 500.",
 "key_facts": [
  {
   "key": "already_in_the_s_p_500",
   "label": "Already in the S&P 500",
   "value": "15.1%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "HELX, already in the S&P 500: 15.1%, as of Sep 11, 2026."
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "97.2%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "HELX, active share vs the S&P 500: 97.2%, as of Sep 11, 2026."
  },
  {
   "key": "top_ten_holdings",
   "label": "Top ten holdings",
   "value": "47.7%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "HELX, top ten holdings: 47.7%, as of Sep 11, 2026."
  },
  {
   "key": "total_return_1_year",
   "label": "Total return, 1 year",
   "value": "+33.6%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "HELX, total return, 1 year: +33.6%, as of Sep 11, 2026."
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$31m",
   "source": "issuer page, as of Sep 11, 2026",
   "as_of": "2026-09-11",
   "sentence": "HELX, net assets: $31m (issuer page, as of Sep 11, 2026)."
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.50%",
   "source": "485BPOS XBRL, Jul 27, 2026",
   "as_of": "2026-09-11",
   "sentence": "HELX, expense ratio: 0.50% (485BPOS XBRL, Jul 27, 2026)."
  }
 ],
 "fields": [
  {
   "key": "theme",
   "label": "Theme",
   "value": "Healthcare innovation and GLP-1",
   "source": "ETFIQ, editorial"
  },
  {
   "key": "launched",
   "label": "Launched",
   "value": "Feb 27, 2020",
   "source": null
  },
  {
   "key": "already_in_the_s_p_500_by_weight",
   "label": "Already in the S&P 500, by weight",
   "value": "15.1%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "97.2%",
   "source": "ETFIQ"
  },
  {
   "key": "already_in_the_nasdaq_100_by_weight",
   "label": "Already in the Nasdaq-100, by weight",
   "value": "10.0%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_nasdaq_100",
   "label": "Active share vs the Nasdaq-100",
   "value": "98.5%",
   "source": "ETFIQ"
  },
  {
   "key": "top_ten_holdings_weight",
   "label": "Top ten holdings weight",
   "value": "47.7%",
   "source": null
  },
  {
   "key": "holdings",
   "label": "Holdings",
   "value": "61",
   "source": null
  },
  {
   "key": "holdings_as_of",
   "label": "Holdings as of",
   "value": "Jun 30, 2026",
   "source": "SEC N-PORT"
  },
  {
   "key": "top_holdings",
   "label": "Top holdings",
   "value": "GUARDANT HEALTH INC 9.2%, NATERA INC 7.6%, KRYSTAL BIOTECH INC 6.4%, LIGAND PHARMACEUTICALS INC 4.7%, ADAPTIVE BIOTECHNOLOGIES CORP 4.0%, UNITED THERAPEUTICS CORP 3.5%, BRIDGEBIO PHARMA INC 3.5%, ELI LILLY & COMPANY 3.0%, TWIST BIOSCIENCE CORP 2.9%, VERTEX PHARMACEUTICALS INC 2.8%",
   "source": null
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$31m",
   "source": "issuer page, as of Sep 11, 2026"
  },
  {
   "key": "below_its_all_time_high",
   "label": "Below its all-time high",
   "value": "\u221229.2%",
   "source": "ETFIQ"
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.50%",
   "source": "485BPOS XBRL, Jul 27, 2026"
  },
  {
   "key": "fee_for_the_part_that_differs_from_the_s_p_500_active_expense_ratio",
   "label": "Fee for the part that differs from the S&P 500, active expense ratio",
   "value": "0.51%",
   "source": "ETFIQ"
  },
  {
   "key": "closest_funds_by_holdings_overlap",
   "label": "Closest funds by holdings overlap",
   "value": "WDNA 34%, GNOM 29%, HTEC 28%, IBBQ 26%, BBH 25%",
   "source": null
  }
 ],
 "periods": [
  {
   "window": "3 months",
   "Total return": "+15.6%",
   "S&P 500": "+3.3%",
   "Gap to S&P 500": "+12.3 pts",
   "Gap to Nasdaq-100": "+16.4 pts"
  },
  {
   "window": "6 months",
   "Total return": "+28.1%",
   "S&P 500": "+16.0%",
   "Gap to S&P 500": "+12.1 pts",
   "Gap to Nasdaq-100": "+7.5 pts"
  },
  {
   "window": "1 year",
   "Total return": "+33.6%",
   "S&P 500": "+17.5%",
   "Gap to S&P 500": "+16.1 pts",
   "Gap to Nasdaq-100": "+10.7 pts"
  },
  {
   "window": "3 years",
   "Total return": "+38.7%",
   "S&P 500": "+77.9%",
   "Gap to S&P 500": "\u221239.2 pts",
   "Gap to Nasdaq-100": "\u221256.4 pts"
  },
  {
   "window": "Since launch",
   "Total return": "+72.4%",
   "S&P 500": "+182.0%",
   "Gap to S&P 500": "\u2212109.6 pts",
   "Gap to Nasdaq-100": "\u2212189.2 pts"
  }
 ],
 "questions": [
  {
   "q": "How much of HELX is in S&P 500 companies?",
   "a": "By its holdings filed for Jun 30, 2026, 15% of HELX by weight is stocks the S&P 500 already holds. Its active share against the index is 97%, so that share is the part doing something different."
  },
  {
   "q": "What does HELX hold?",
   "a": "61 positions as filed for Jun 30, 2026, with the top ten at 48% of the fund. The largest are GUARDANT HEALTH INC at 9.2%, NATERA INC at 7.6%, KRYSTAL BIOTECH INC at 6.4%."
  },
  {
   "q": "Has HELX beaten the S&P 500?",
   "a": "Over the year to Sep 11, 2026 HELX returned +33.6% with distributions reinvested, against +17.5% for the S&P 500, so it finished ahead of the index by 16.1 points."
  },
  {
   "q": "What does HELX cost?",
   "a": "The prospectus expense ratio is 0.50% a year. Because 97% of the fund differs from the S&P 500, the fee on that differing part works out at 0.51%."
  }
 ],
 "generated": "2026-09-13",
 "license": "Free to use with attribution. ETFIQ (etfiq.com)."
}